Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.

Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.

Curr Med Res Opin. 2012 Jul;28(7):1089-99. doi: 10.1185/03007995.2012.698602. Epub 2012 Jun 21.

PMID:
22642866
2.

A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.

Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Aerts JG.

Curr Med Res Opin. 2012 Jul;28(7):1079-87. doi: 10.1185/03007995.2012.698601. Epub 2012 Jun 21.

PMID:
22642867
3.

Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study.

Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B.

Curr Med Res Opin. 2011 May;27(5):987-94. doi: 10.1185/03007995.2011.562493. Epub 2011 Mar 9.

PMID:
21385113
4.

A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.

Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E; AMG-DAR-2002-01 Study Group.

Curr Med Res Opin. 2008 Oct;24(10):2931-42. doi: 10.1185/03007990802381323 . Epub 2008 Sep 4.

PMID:
18775103
5.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.

Med Oncol. 2012 Sep;29(3):2291-9. doi: 10.1007/s12032-011-0103-x. Epub 2011 Nov 13.

PMID:
22081263
6.

A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.

Ray-Coquard I, Laplaige P, Vey N, Asselain B, Urbieta M.

Curr Med Res Opin. 2010 Nov;26(11):2653-60. doi: 10.1185/03007995.2010.526099. Epub 2010 Oct 11.

PMID:
20932223
7.

RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.

Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.

Curr Med Res Opin. 2011 Feb;27(2):355-63. doi: 10.1185/03007995.2010.542134. Epub 2010 Dec 20.

PMID:
21166611
8.

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.

Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A; RADAR Study Group.

Curr Med Res Opin. 2012 Jan;28(1):57-67. doi: 10.1185/03007995.2011.639352. Epub 2011 Nov 23.

PMID:
22070513
9.
10.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

Hudis CA, Vogel CL, Gralow JR, Williams D; Procrit Study Group.

Clin Breast Cancer. 2005 Jun;6(2):132-42.

PMID:
16001991
11.

Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.

Hess G, Hill J, Clough J, Hulnick S, Nordyke RJ.

Curr Med Res Opin. 2008 Mar;24(3):815-9. doi: 10.1185/030079908X280383. Epub 2008 Feb 6.

PMID:
18257979
12.

A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.

Steinmetz T, Kindler M, Lange O, Vehling-Kaiser U, Kuhn A, Hellebrand E.

Curr Med Res Opin. 2014 Sep;30(9):1813-20. doi: 10.1185/03007995.2014.924914. Epub 2014 Jun 5.

PMID:
24849527
13.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

14.
15.

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.

Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.

BMC Cancer. 2009 Sep 3;9:311. doi: 10.1186/1471-2407-9-311.

16.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

17.

Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.

Biesma B, van de Werf PR, Melissant CF, Brok RG.

Lung Cancer. 2007 Oct;58(1):104-11. Epub 2007 Jun 29.

PMID:
17601632
18.

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.

Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH.

Clin Ther. 2016 Jan 1;38(1):122-135.e6. doi: 10.1016/j.clinthera.2015.11.012. Epub 2015 Dec 22. Review.

19.

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.

Eur Heart J. 2007 Sep;28(18):2208-16. Epub 2007 Aug 6.

PMID:
17681958
20.

A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.

Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.

Lung Cancer. 2004 Oct;46(1):119-24.

PMID:
15364140

Supplemental Content

Support Center